NASDAQ · PLRX
Pliant Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PLRX: Nov 5, 2026
Pliant Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.37. The reported EPS for the same quarter last year was $-0.43.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.37 | $-0.36 | $-0.37 | 2 |
| Dec 2026 | $-0.37 | $-0.36 | $-0.37 | 2 |
| Mar 2027 | $-0.38 | $-0.36 | $-0.39 | 2 |
| Jun 2027 | $-0.38 | $-0.36 | $-0.39 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · Quiver Quantitative · Zacks- RTTNews · Oct 1, 5:00 AM EDTPliant Therapeutics Names David Raben As CMO To Lead PLN-101095 Development(RTTNews) – Pliant Therapeutics (PLRX), a clinical-stage biotechnology company focused on developing integrin-based therapeutics, announced the appointment of David Raben, M.D., as Chief Medical Officer.
- RTTNews · Aug 18, 10:11 AM EDTPliant Wins FDA Fast Track For PLN-101095 In ICI-Refractory Solid Tumors(RTTNews) – Pliant Therapeutics, Inc. (PLRX), a clinical-stage biopharmaceutical company, on Tuesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PLN-101095 in combination with pembrolizumab for the potential treatment of immune
- Fintel · Nov 7, 7:10 PM ESTRBC Capital Maintains Pliant Therapeutics (PLRX) Sector Perform RecommendationFintel reports that on November 7, 2025, RBC Capital maintained coverage of Pliant Therapeutics (NasdaqGS:PLRX) with a Sector Perform recommendation. Analyst Price Forecast Suggests 104.00% Upside
- RTTNews · Sep 10, 12:36 AM EDTBiotech Stocks Rally After-Hours On Trial Updates, Insider Buys, And Conference Buzz(RTTNews) – Biotech stocks lit up the after-hours session on September 9, 2025, with several small- and mid-cap names posting sharp gains following fresh clinical updates, insider buying, and investor conference appearances. Companies like Immutep, Nautilus Biotechnology, Pliant
- Quiver Quantitative · May 1, 4:14 PM EDTPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsPliant Therapeutics announces a workforce reduction and cost-saving measures to extend its cash runway for late-stage clinical trials.
- Zacks · Apr 10, 12:00 PM EDTPLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should KnowPLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Mar 27, 9:39 AM EDTPLRX Stock Plunges 89% in 3 Months: Here's What Investors Should KnowPliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
- RTTNews · Mar 17, 8:39 AM EDTPliant Reports Early Responses From Phase 1 Dose Escalation Trial With PLN-101095(RTTNews) – Pliant Therapeutics, Inc. (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin v8 and v1 inhibitor, in combination with pembrolizumab, in patients with immune chec
- Quiver Quantitative · Mar 13, 7:30 AM EDTPliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder InterestsPliant Therapeutics adopts a stockholder rights agreement to safeguard against unsolicited stock accumulation, enhancing shareholder protections.
- RTTNews · Mar 3, 11:01 AM ESTPliant Therapeutics Discontinues BEACON-IPF Phase 2b Trial For Bexotegrast In IPF Patients(RTTNews) – Pliant Therapeutics, Inc. (PLRX) announced the discontinuation of its BEACON-IPF Phase 2b trial evaluating bexotegrast for the treatment of idiopathic pulmonary fibrosis or IPF following a review by the independent Data Safety Monitoring Board or DSMB and an external
- Quiver Quantitative · Mar 3, 9:31 AM ESTPliant Therapeutics Discontinues BEACON-IPF Phase 2b Trial of Bexotegrast Due to Safety ConcernsPliant Therapeutics discontinues BEACON-IPF trial for bexotegrast due to safety concerns, noting potential efficacy in patients with IPF.
- Zacks · Feb 14, 12:00 PM ESTAll You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to BuyPLIANT THERAPT (PLRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Pliant Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.